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ABSTRACT
Chronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allogeneic stem
cell transplantation. Mild forms of chronic GVHD are often manageable with local or low-dose systemic
immunosuppression and do not affect long-term survival. In contrast, more severe forms of chronic GVHD
require intensive medical management and adversely affect survival. This report reviews current concepts of
the pathogenesis, clinical risk factors, classification systems, organ manifestations, and available treatments for
chronic GVHD. It also provides a comprehensive listing of the published clinical trials aimed at prevention and
primary treatment of chronic GVHD.
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BACKGROUND
Chronic graft-versus-host disease (GVHD) is one
of the most common and clinically signiﬁcant prob-
lems affecting long-term survivors of allogeneic he-
matopoietic cell transplantation (HCT). Up to 60% of
patients receiving HLA-identical sibling marrow
grafts and 70% of patients receiving alternative donor
marrow grafts who survive beyond day 100 develop
chronic GVHD [1-3]. Chronic GVHD is the leading
cause of nonrelapse mortality more than 2 years after
allogeneic transplantation [4]. In addition, chronic
GVHD is associated with decreased quality of life,
impaired functional status, and ongoing need for im-
munosuppressive medications [4-7]. The incidence of
chronic GVHD is increasing (Figure 1) because of
several factors: expansion of the donor population
beyond HLA-identical siblings, older recipient age,
use of peripheral blood cells as the graft source, and
infusion of donor lymphocytes for treatment of recur-
rent malignancy after HCT. Although prevention and
treatment of acute GVHD have improved during the
past 3 decades, similar progress in chronic GVHD has
remained elusive.
PATHOGENESIS
Compared with the advances in our understanding
of acute GVHD, the pathophysiology of chronic
GVHD remains poorly deﬁned. Clinical studies of
chronic GVHD in humans have been difﬁcult, in part
because of the delayed onset relative to other trans-
plant complications of interest. Several animal models
of chronic GVHD have been reported [8-15]. In one
murine model (parent into F1 hybrid) that more
closely resembles lupus (due to renal involvement)
than chronic GVHD, extensive antibody-mediated
damage appears to be associated solely with a Th2
response [16]. In contrast, both Th1 and Th2 cells
have been implicated in humans [17-20]. In another
murine model of sclerodermatous chronic GVHD,
chemokines and donor mononuclear cells appear to
play important roles, and administration of neutraliz-
ing antibody against transforming growth factor
(TGF)- prevented the development of chronic
GVHD [15]. In this model, T cells and donor-derived
monocyte/macrophages expressing markers of antigen
presentation are the predominant cells inﬁltrating the
skin early in the disease. Up-regulation of TGF-
expression and several chemokines are temporally re-
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lated to increased collagen messenger RNA synthesis,
skin thickening, and pulmonary ﬁbrosis.
In humans, T-lymphocyte imbalances, from over-
expansion of pathological subsets and/or loss of ap-
propriate regulation, have long been suspected of
causing chronic GVHD. The etiologic contribution
of alloreactive T cells to the development of chronic
GVHD is supported by the observation that T-cell
depletion is associated with less chronic GVHD in
HLA-matched sibling marrow transplantation [21],
whereas peripheral blood stem cell (PBSC) transplan-
tation [22-29] and donor lymphocyte infusions (DLI)
are associated with higher rates of chronic GVHD
[30,31]. Autoreactive T cells have been implicated in
the pathogenesis of cyclosporine-induced autologous
GVHD, which clinically resembles allogeneic chronic
GVHD but is mediated by autoreactive T cells that
recognize the CLIP region of major histocompatibil-
ity complex class II molecules [32]. Cyclosporine
(CSA) inhibits thymic-dependent clonal deletion of
autoreactive T cells, thereby paradoxically disrupting
self-tolerance. The effector cells have broad-based
recognition of tissues, and the clinical manifestations,
when fully evolved, are identical to chronic GVHD. It
is speculated that autoreactive T cells may arise in the
allogeneic setting because of thymic injury from acute
GVHD (or from other causes) that allows the survival
of autoreactive clones rather than their deletion
[33,34]. These autoreactive T lymphocytes can act
with interferon (IFN) to produce the increased colla-
gen deposition seen histopathologically in chronic
GVHD [35].
Given the similarities between chronic GVHD
and autoantibody-associated diseases, several studies
have attempted to link B cells and humoral immunity
with chronic GVHD. However, a study of 53 long-
term survivors failed to ﬁnd an association between
classic autoantibodies and chronic GVHD [36]. Some
antigens, such as promyelocytic leukemia (PML) gene
product, are expressed aberrantly in chronic GVHD
lesional tissue but not in uninvolved skin or normal
controls, although circulating antibodies to PML have
not been detected [37]. Some reports link cytomega-
lovirus (CMV) infection with chronic GVHD. CD13
is aberrantly expressed in CMV-infected individuals,
and antibodies to CD13 have been associated with
chronic GVHD [38,39].
Cytokine dysregulation also has been implicated
through observations that high levels of interleukin
(IL)-1, IL-6, IFN, and tumor necrosis factor
(TNF)- are associated with more severe chronic
GVHD [40]. High serum TGF- also was associated
with chronic GVHD independent of platelet and
white blood cell counts [41], and antibodies to TGF-
prevented the development of sclerodermatous
GVHD in a murine model [15]. Patients with chronic
GVHD have low levels of IL-10, an anti-inﬂamma-
tory cytokine thought to suppress IFN- and immu-
noglobulin (Ig) production, compared with patients
without chronic GVHD [42].
Finally, the clinical manifestations of chronic
GVHD closely resemble those of several well-recog-
nized autoimmune syndromes, suggesting similar
pathophysiology. Scleroderma, which has cutaneous
manifestations similar to late ﬁbrosing chronic
GVHD, occurs predominantly in women and has
been associated with an increased incidence of circu-
lating fetal male cells, suggesting that persistent mi-
crochimerism may play a role [43,44].
CLINICAL RISK FACTORS
Table 1 presents the patient, donor/graft, and pro-
cedural factors that have been associated with the
development of chronic GVHD. Consistently identi-
ﬁed clinical risk factors include older patient age,
female donors and male patients, certain diagnoses
(chronic myeloid leukemia and aplastic anemia), use of
mismatched or unrelated donors, infusion of donor
lymphocytes, use of PBSCs instead of bone marrow,
lack of T-cell depletion, and grade II to IV acute
GVHD [21,45-50]. Although acute GVHD is the
most powerful predictor of subsequent chronic
GVHD, de novo chronic GVHD (no prior acute
GVHD) is associated with similar patient and donor
risk factors [47,51]. More controversial risk factors for
chronic GVHD include CMV seropositivity, CMV
reactivation, splenectomy, steroid prophylaxis for
acute GVHD, ethnic difference between donor and
patient, high CD34 cell count in the graft, and
absence of methotrexate in PBSC transplantation
[21,46,50,52-54]. Early reports of umbilical blood
stem cell grafting suggest lower rates of chronic
GVHD [55].
Figure 1. Percentage of patients surviving at least 100 days who
were diagnosed with chronic GVHD at the Fred Hutchinson Can-
cer Research Center during the past 2 decades.
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Peripheral blood progenitor cells have been asso-
ciated with an increased incidence of chronic GVHD
(50%-90%) in most studies of HLA-matched sibling
transplantation [22-27,29]. Cutler et al. performed a
meta-analysis using data from 16 studies and reported
a pooled relative risk (RR) for extensive chronic
GVHD (RR 1.66; 95% conﬁdence interval, 1.35-2.05;
P  .001) compared with bone marrow [28]. Recent
data suggest that high CD34 counts may be the
most important factor driving this observation, be-
cause chronic GVHD did not correlate with CD3
and CD14 counts [54]. The use of granulocyte col-
ony-stimulating factor (G-CSF) during stem cell col-
lection also has been suspected of increasing chronic
GVHD after PBSC transplantations because G-CSF
is known to preferentially shift T-helper cells to a Th2
phenotype [56]. However, a trial performed by Mor-
ton et al. suggests that donor treatment per se with
G-CSF is not the cause of the higher chronic GVHD
incidence. They randomized HLA-matched sibling
donors to marrow or PBSC collection after both
groups received G-CSF stimulation (N  57). Rates
of chronic GVHD were higher in the PBSC arm
(80% versus 22%; P  .02), although overall survival
was the same [29]. In the unrelated donor marrow
setting, patients have a higher risk for chronic GVHD
than HLA-matched siblings [3], but it is not clear
whether PBSCs further elevate this risk [57,58].
Finally, several factors have been studied and not
found to be associated with chronic GVHD. These
include type of myeloablative conditioning regimen,
type of calcineurin inhibitor used for acute GVHD
prophylaxis, and whether 3 or 4 doses of methotrexate
are administered. The reported incidence of chronic
GVHD is similar for busulfan/cyclophosphamide and
total body irradiation/cyclosphosphamide preparative
regimens [59]. Use of either tacrolimus or CSA pro-
phylaxis resulted in similar rates of chronic GVHD,
although there was less extensive chronic GVHD in
the tacrolimus group [60]. Failure to give day 11
methotrexate was not shown to inﬂuence rates of
chronic GVHD, although only a small number of
patients was studied [61,62].
CLASSIFICATION OF CHRONIC GVHD
Chronic GVHD can be classiﬁed according to the
type of onset, need for systemic immunosuppressive
therapy, or mortality risk. The majority of patients
with chronic GVHD have had prior acute GVHD.
Their disease may evolve directly from acute GVHD
(progressive), which has a grim prognosis, or may fol-
low a period of resolution (quiescent, or interrupted)
GVHD, with an intermediate prognosis. Patients may
develop chronic GVHD with no history of prior acute
GVHD (“de novo”), and these patients have a rela-
tively good prognosis. Based on data from the Inter-
national Bone Marrow Transplant Registry (IBMTR),
the distribution of chronic GVHD onset for HLA-
matched siblings is 20% to 30% progressive, 30% to
40% interrupted, and 35% de novo. Data from the
National Marrow Donor Program for unrelated do-
nor recipients, where the incidence of acute GVHD is
higher, shows the spectrum of onset as 19% progres-
sive, 69% interrupted, and 12% de novo onset [3].
The most commonly used staging system is the
“limited/extensive” classiﬁcation proposed by the Se-
attle Group in 1980 based on a retrospective clinical
and pathological review of 20 patients with chronic
GVHD. In this group, mortality correlated best with
Karnofsky performance status [63]. Localized skin in-
volvement with or without hepatic dysfunction (lim-
ited disease) was associated with less severe disease and
fewer infections. Generalized skin involvement or
limited disease plus eye involvement, oral involve-
ment, hepatic dysfunction with abnormal liver histol-
ogy, or involvement of any other target organ was
classiﬁed as extensive disease and was associated with
more frequent infections. However, review of data
Table 1. Reported Risk Factors for Chronic GVHD According to the Patient and Donor Characteristics, Hematopoietic Stem Cell Source, and
Posttransplantation Events
Patient Donor and Graft Characteristics Transplant Events
Consistently observed Older age
Chronic myeloid leukemia
or aplastic anemia
Female donor (especially parous)
if male patient
Acute GVHD
Mismatched or unrelated
PBSC
DLIs
T-cell replete graft
Controversial or limited
evaluation
CMV seropositive
CMV reactivation
Ethnic difference between donor
and patient
Corticosteroids in the acute
GVHD prophylaxis regimen
Splenectomy Lower incidence with umbilical
cord blood
High CD34 count (PBSC)
Lack of methotrexate in
acute GVHD prophylaxis
(PBSC)
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from HLA-matched sibling recipients reported to the
IBMTR suggests that transplantation centers are not
applying the formal deﬁnitions accurately, perhaps in
part because many patients are unclassiﬁable by the
strict organ criteria [3]. The Seattle Group has devel-
oped revised clinical criteria for limited and extensive
chronic GVHD to clarify ambiguities of the original
deﬁnition (Table 2). In the revised classiﬁcation, pro-
longed treatment with systemic immunosuppression is
indicated for patients with clinically extensive chronic
GVHD or anyone with high-risk features (ie, platelets
count 100  109/L, progressive onset, or receipt of
treatment with corticosteroids at the time of the di-
agnosis of chronic GVHD).
Several investigators have tried to develop im-
proved prognostic grading scales based on larger
numbers of observed patients and with survival as the
primary endpoint. Table 3 lists the scales that have
been proposed thus far [3,63-67]. In aggregate these
studies show that thrombocytopenia (platelet count
100  109/L), progressive onset, skin involvement,
poor performance status, and gastrointestinal (GI) in-
volvement portend a poorer prognosis. The Hopkins
model stratiﬁes patients into risk categories according
to whether or not extensive skin involvement, throm-
bocytopenia, and progressive-type onset is present
[66]. This model was validated using data from 1108
patients from the IBMTR (n  711), Fred Hutchin-
son Cancer Center (n  188), University of Nebraska
(n  60), and University of Minnesota (n  149).
Despite signiﬁcant heterogeneity of the data, for each
data set the proposed grading system was able to
separate patients into 3 groups with different survival
outcomes (personal communication, G. Akpek, De-
cember 2002).
The IBMTR also has reported a grading system
predictive for survival developed by using data from
1827 HLA-matched sibling marrow recipients re-
ported to the registry [3]. Karnofsky performance
score, diarrhea, weight loss, and cutaneous and oral
involvement were found to be independent prognostic
variables, from which a grading scheme was gener-
ated. This scheme, the limited/extensive classiﬁcation
system, and a classiﬁcation based on clinical impres-
Table 2. Original and Revised Seattle Classiﬁcation for Limited and Extensive Chronic GVHD
Original Seattle Classification Revised Seattle Classification*
Limited Clinical limited
One or both of: 1. Oral abnormalities consistent with chronic GVHD, a positive skin or lip biopsy, and
no other manifestations of chronic GVHD
Localized skin involvement 2. Mild liver test abnormalities (alkaline phosphatase <2  upper limit of normal, AST
or ALT <3  upper limit of normal, and total bilirubin <1.6) with positive skin or lip
biopsy, and no other manifestations of chronic GVHD
Hepatic dysfunction due to
chronic GVHD
3. Less than 6 papulosquamous plaques, macular-papular or lichenoid rash involving
<20% of BSA, dyspigmentation involving <20% BSA, or erythema involving <50%
BSA, positive skin biopsy, and no other manifestations of chronic GVHD
4. Ocular sicca (Schirmer’s test <5 mm with no more than minimal ocular symptoms),
positive skin or lip biopsy, and no other manifestations of chronic GVHD
5. Vaginal or vulvar abnormalities with positive biopsy, and no other manifestations of
chronic GVHD
Extensive Clinical extensive
One of: 1. Involvement of 2 or more organs with symptoms or signs of chronic GVHD, with
biopsy documentation of chronic GVHD in any organ
Generalized skin involvement 2. Karnofsky or Lansky Clinical Performance scores <60%, >15% weight loss, and
recurrent infections not due to other causes, with biopsy documentation of chronic
GVHD in any organ
Localized skin involvement and/or
hepatic dysfunction due to
chronic GVHD, plus:
Liver histology showing
chronic aggressive hepatitis,
bridging necrosis, or
cirrhosis, or:
Involvement of eye
(Schirmer’s test with <5
mm wetting), or:
Involvement of minor salivary
glands or oral mucosa
demonstrated on labial
biopsy, or:
Involvement of any other
target organ
3. Skin involvement more extensive than defined for clinical limited chronic GVHD,
confirmed by biopsy
4. Scleroderma or morphea
5. Onycholysis or onychodystrophy thought to represent chronic GVHD, with
documentation of chronic GVHD in any organ
6. Decreased range of motion in wrist or ankle extension due to fasciitis caused by
chronic GVHD
7. Contractures thought to represent chronic GVHD
8. Bronchiolitis obliterans not due to other causes
9. Positive liver biopsy; or abnormal liver function tests not due to other causes with
alkaline phosphatase >2  upper limit of normal, AST or ALT >3  upper limit of
normal, or total bilirubin >1.6, and documentation of chronic GVHD in any organ
10. Positive upper or lower GI biopsy
11. Fasciitis or serositis thought to represent chronic GVHD and not due to other causes
*Provided by Mary E.D. Flowers and Paul J. Martin, Fred Hutchinson Cancer Research Center.
AST indicates aspartate aminotransferase; ALT, alanine aminotransferase; BSA, body surface area.
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sion of overall chronic GVHD severity (mild, moder-
ate, or severe) was assessed in a parallel analyses of
1092 HLA-matched sibling transplant recipients from
the IBMTR and 553 recipients of unrelated donor
marrow from the National Marrow Donor Program.
Presence of chronic GVHD was associated with fewer
relapses (RR, 0.5-0.6) but more treatment-related
mortality (RR, 1.8-2.8) in the 3 analyses. No grading
scheme correlated chronic GVHD severity with re-
lapse rates, but all schemes predicted treatment-re-
lated mortality. Survival and disease-free survival of
the most favorable chronic GVHD group in each
scheme were similar, or better, than those of patients
without chronic GVHD. Notably, an overall clinical
summary scale of mild, moderate, or severe chronic
GVHD was the best predictor of survival based on
Akaike’s information criterion, a qualitative biostatis-
tical method of comparing prognostic schemes [3].
However, formal deﬁnitions for the mild, moderate,
and severe categories have not been established [68]
(Figure 2).
Comparison of the Hopkins and IBMTR reports
illustrates the advantages and disadvantages of single-
institution versus registry studies. The Hopkins model
has a smaller sample size (N  151) and was based on
the consistent diagnostic criteria of a single group of
Table 3. Risk Factors for Survival at the Time of Diagnosis of Chronic GVHD
Reference N Platelets Onset Skin Liver
Other Poor Prognostic
Factors
Shulman et al. [63] 20 — — Generalized
involvement
Cirrhosis “Extensive,” poor Karnofsky
performance status,
recurrent infections,
active chronic GVHD
after 2 mo of therapy
Wingard et al. [64] 85 — Progressive Lichenoid
involvement
Bilirubin >1.2 mg/dL
Morton et al. [65] 102 <100  109/L — — Bilirubin >2.0 mg/dL On steroids at onset, IFN-
>6 mo duration before
transplantation (CML)
Akpek et al. [66] 151 <100  109/L Progressive >50% BSA — Karnofsky score when
primary therapy fails
Lee et al. [3] 727 — — Involved — Karnofsky score, diarrhea,
weight loss, lack of oral
involvement
Arora et al. [67] 159 <100  109/L Progressive — — GI involvement, no response
at 6 months
Reprinted with permission from Lee et al. Chronic graft-versus-host disease. In: Atkinson et al. Clinical Bone Marrow and Blood Stem Cell
Transplantation. 3rd ed. Cambridge, UK: Cambridge University Press [in press].
Figure 2. Association of severity of chronic GVHD with relapse (I), treatment-related mortality (II), and disease-free survival (III) for patients
with none, low, intermediate, or high-risk chronic GVHD. From: Lee SJ, Klein JP, Barnett AJ, et al. Severity of chronic graft-versus-host
disease: association with treatment-related mortality and relapse. Blood 2002;100:406-414. Copyright American Society of Hematology, used
by permission.
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clinicians, but may suffer from referral bias. In con-
trast, the IBMTR model is based on reports from
many centers but is limited by the expertise of those
evaluating the patients and the amount of detail that
can be captured on speciﬁc chronic GVHD manifes-
tations.
CLINICAL MANIFESTATIONS
Manifestations of “acute” GVHD without patho-
gnomonic features of chronic GVHD can begin after
day 100 posttransplantation, whereas classic “chronic”
GVHD can be present before day 100. For this rea-
son, the distinction between acute and chronic
GVHD cannot be made solely according to the time
interval from transplantation. The median time of
diagnosis of chronic GVHD is 4.5 months after HLA-
identical sibling transplantation and 4 months after
unrelated donor transplantation [3], with only 5% of
cases diagnosed after 1 year. The diagnosis of chronic
GVHD requires at least 1 manifestation that is dis-
tinctive for chronic GVHD (eg, lichenoid-oral or vag-
inal ﬁndings, ocular sicca, skin dyspigmentation,
scleroderma, bronchiolitis obliterans, and esophageal
web formation). Whenever possible, biopsies and
other diagnostic tests should be pursued to rule out
alternative etiologies, such as infections, and to con-
ﬁrm the diagnosis of chronic GVHD. In HLA-
matched marrow grafting with primarily methotrex-
ate-based prophylaxis, skin (65%-80%), mouth (48%-
72%), liver (40%-73%), and eye (18%-47%)
involvement are most commonly reported. Other less
frequently involved organs include GI tract/weight
loss (16%-26%), lung (10%-15%), esophagus (6%-
8%), and joints (2%-12%) [3,21,69]. Flowers et al.
have reported that PBSC recipients have a similar
time to onset and spectrum of organ involvement [70].
Table 4 outlines the signs, symptoms, and histopatho-
logic ﬁndings associated with chronic GVHD.
Skin and Dermal Appendages
Chronic GVHD often presents with a lichenoid
eruption, an erythematous, papular rash that resem-
bles lichen planus and has no typical distribution pat-
tern. Sclerodermatous GVHDmay involve the dermis
and/or the muscular fascia and it clinically resembles
systemic sclerosis. The skin is thickened, tight, and
fragile with very poor wound-healing capacity. Alter-
ation in pigmentation, either hypopigmentation or
hyperpigmentation, may occur. In severe cases, the
skin may blister from poor lymphatic drainage or
ulcerate from minor trauma. Because the sclerosis
histologically affects the dermis, hair loss and destruc-
tion of the sweat glands are common. In cases of
severe ulceration, skin grafts from the donor have
been successful, and the tissue remains healthy and
uninvolved with chronic GVHD [71,72]. Serial assess-
ments should document the extent, type, and distri-
bution of skin involvement.
Fingernails and toenails may be affected by
chronic GVHD. Nails develop vertical ridges and
cracking and are very fragile. Nail problems may per-
sist even after skin changes have resolved. Hair loss in
areas of affected skin also may persist after treatment,
although recovery of hair is frequently a sign of re-
covery. Brittle hair often precedes alopecia. Premature
graying of hair, eyebrows, and eyelashes may occur
with chronic GVHD, even in children.
Eyes
Ocular GVHD often presents with irritation,
burning, dry eyes, or photophobia from irreversible
destruction of the lacrimal glands. Excessive tearing
can be a sign of ocular sicca. Conjunctival GVHD is a
rare manifestation of severe chronic GVHD and can
be quite refractory to treatment. Protective eyeglasses
and sunglasses, frequent lubrication, application of
ophthalmic ointment at night, and punctal plugs or
cauterization can help symptomatically and prevent
further damage. Moisture chamber eyeglasses (a pros-
thetic device coupled to the eyeglasses) can signiﬁ-
cantly relieve the symptoms of dry eyes [73]. Schirm-
er’s tests can be performed in clinic and are useful to
follow chronic GVHD.
Mouth
Oral GVHD usually starts with xerostomia and/or
food sensitivity. More advanced disease may cause
odynophagia due to extension of damage, although a
rare patient will have esophageal involvement without
oral disease. Physical examination in mild disease
shows erythema with white plaques that may be con-
fused with thrush or herpetic infections, whereas ex-
tensive lichenoid or hyperkeratotic changes are found
in advanced disease [74]. Pseudomembranes, large,
nonhealing ulcers, may be found anywhere in the
mouth including tongue and palate but are often along
the bite lines. Both major and minor salivary dysfunc-
tion occurs [75]. Local infections may cause changes
in symptoms without changes in physical ﬁndings.
Secondary infections with viruses (especially herpes
simplex and human papilloma virus) and yeasts are
almost universal and patients usually require treat-
ment as long as their oral disease persists and/or im-
munosuppression is prescribed. Fibrosis causing de-
creased oral range of motion is a very late
manifestation. Patients with chronic GVHD under-
going dental work should receive antibiotic prophy-
laxis.
S. J. Lee et al.
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Table 4. Signs, Symptoms, and Clinicopathologic Findings of Chronic GVHD
System Signs/Laboratory Findings Symptoms Histopathology
Skin (common) Hyper- and hypopigmentation,
lichen planus (violaceous flat-
topped papules), poikiloderma
(atrophy, telangectasias,
dyspigmentation), cutaneous
ulcers, scleroderma (thickening
due to collagen deposition, may
cause decreased range of
motion and contractures),
ichthyosis
Pruritis, lack of flexibility Lichenoid: Hyperkeratosis, focal
hypergranulosis, acanthosis, dyskeratotic
keratinocytes, vacuolar degeneration,
colloid bodies, perivascular and
periadnexal lymphoplasmacellular
infiltrate
Poikiloderma: epidermal atrophy, loss of
rete ridges
Scleroderma: epidermal atrophy, dermal
fibrosis, less inflammation than lichenoid
lesion, adnexal structures destroyed
Differential diagnosis: drug reaction, eczema
Cutaneous
structures
Onchodystrophy, alopecia, loss of
sweat glands
Heat sensitivity Destruction and fibrosis of cutaneous
appendages
Liver (common) Elevated alkaline phosphatase,
transaminases, bilirubin
Pruritis Small bile duct atypia and damage with
subsequent necrosis and drop-out,
moderate lymphocytic infiltrate,
cholestasis and ballooning
Differential diagnosis: drug toxicity
(cholestasis, inflammation), veno-occlusive
disease, viral infections, gallstones, and
infiltrative processes
Mouth (common) Lichen planus, erythema, ulcers,
xerostomia, dental caries,
fibrosis, decreased salivary flow
Food sensitivity, pain, dry
mouth, decreased oral
range of motion from
fibrosis
Mucosal atrophy, lymphoplasmacytic
inflammation, increased
mucopolysaccharides, fibrosis and
destruction of minor salivary glands
Differential diagnosis: Herpes virus infection,
Sjogren’s syndrome
Eyes (common) Keratoconjunctivitis sicca, corneal
ulcerations, Schirmer’s test
with <5 mm wetting at 5 min
Dry eyes, photophobia,
pain
Differential diagnosis: postradiation
xerophthalmia, Sjogren’s syndrome
Esophagus Esophageal web, desquamation,
ulcerations, strictures,
submucosal fibrosis, abnormal
motility
Odynophagia, dysphagia,
heartburn, retrosternal
pain
Differential diagnosis: reflux esophagitis,
infection
Intestines Fibrosis, malabsorption Diarrhea, nausea,
anorexia, abdominal
pain, weight loss
Differential diagnosis: irritable or
inflammatory bowel syndrome, infection
Lung Obstructive more than restrictive
abnormalities on pulmonary
function testing, BO,
pneumothoraces,
bronchiectasis, pseudomonal
colonization, pulmonary
infiltrates; air trapping on high
resolution CAT scan of chest
Dyspnea, nonproductive
cough, wheezing
BO with granulation tissue plugs and fibrosis
obliterating small airways, interstitial
pneumonitis
Musculoskeletal Polymyositis, arthritis, fasciitis Arthralgias, myalgias,
weakness
Serous Pericardial, peritoneal, and
pleural effusions
Clinical syndromes of
cardiac tamponade,
ascites, dyspnea
Usually transudative
Nervous Entrapment of nerves, peripheral
neuropathy, myasthenia gravis
Pain, paresthesias
Urologic Cystitis, phimosis Pain, hematuria
Vagina Erythema, lichen-planus like,
sicca, strictures, stenosis, ulcers
Pain, dyspareunia,
difficulty voiding
Hematopoietic Thrombocytopenia, neutropenia,
eosinophilia, hemolytic anemia
Immune system Lymphoid hypocellularity, hyper-
or hypogammaglobulinemia
Frequent infections,
especially sinus, upper
respiratory tract
Reprinted with permission from Lee et al. Chronic graft-versus-host disease. In: Atkinson et al. Clinical Bone Marrow and Blood Stem Cell
Transplantation. 3rd ed. Cambridge, UK: Cambridge University Press [in press].
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Gastrointestinal Tract
Esophageal symptoms of dysphagia and odyno-
phagia result from desquamation, web and stricture
formation, and reﬂux esophagitis. Periodic endoscopic
dilations and antacid medications may help symptom-
atically. Stomach and small intestinal pathology are
relatively rare. However, many patients have anorexia,
nausea, lower abdominal pain, cramping, and diar-
rhea. Pancreatic insufﬁciency without characteristic
laboratory and radiographic studies may occur, and
this syndrome responds to enzyme supplementation
[76]. Weight loss is common and is probably multi-
factorial from decreased oral intake, poor absorption,
increased resting energy expenditures [77], and in-
creased TNF levels. Degree of weight loss should be
followed up closely so appropriate interventions can
be instituted. Hopkins reviewed 93 patients with
chronic GVHD and reported malnutrition in 43% of
patients and severe malnutrition with body mass index
18.5 in 14% of patients[78]. Symptoms often im-
prove with successful treatment of GVHD.
Many patients with chronic GVHD have GI
symptoms that are not necessarily related to their
chronic GVHD. When the Hopkins group reviewed
40 patients with chronic GVHD who underwent en-
doscopy for GI symptoms, more than half (59%) were
found to have ongoing acute GVHD and an additional
27% had both acute and chronic GVHD when biopsy
specimens were obtained. Chronic GVHD alone was
found in only 14% of cases. Other causes of GI symp-
toms included infection, drug side effects, motility
disorders, and malabsorption. Patients with ongoing
acute GI GVHD had poor survival.
Liver
Hepatic disease typically presents as cholestasis,
with laboratory evaluation showing increased alkaline
phosphatase levels and/or increased serum bilirubin
levels. Occasionally, chronic GVHD of the liver pre-
sents as a picture of acute hepatitis [79]. Liver biopsy
is required to conﬁrm the diagnosis and is especially
important in patients with no other symptoms of
chronic GVHD because viral infection and drug tox-
icity may mimic GVHD. Isolated hepatic chronic
GVHD may be increasing with the use of DLI [80].
Liver transplantation has been successfully performed
for end-stage hepatic chronic GVHD [81].
Respiratory Tract
Bronchiolitis obliterans (BO) is a late manifesta-
tion of chronic GVHD. Patients typically present with
a cough, wheezing, dyspnea on exertion, or history of
recurrent bronchitis or sinusitis [82]. Pulmonary func-
tion testing shows new obstructive lung defects de-
ﬁned by an FEV1 80% of predicted or a decrease of
FEV1/FVC by 10% within a period of less than 1
year, not explained by infection, asthma, or recurrent
aspiration from the sinuses or from gastroesophageal
reﬂux. In the absence of chronic GVHD in any other
organ, the diagnosis of BO requires negative micro-
biological tests from bronchoalveolar lavage, evidence
of air trapping by high-resolution end-expiratory and
end-inspiratory computer-assisted tomography scan
of the lungs, or conﬁrmation using lung biopsy show-
ing granulation tissue and obliteration of the small
airways. Although low Ig levels and chronic GVHD
are associated with BO, a randomized trial of prophy-
lactic Ig replacement did not decrease the incidence of
BO [83]. Patients with BO have minimal response to
therapy and a very poor prognosis; serial pulmonary
function tests can quantify the degree of respiratory
compromise. Bronchiolitis obliterans organizing
pneumonia not caused by infections also may repre-
sent a manifestation of chronic GVHD. Patients with
bronchiolitis obliterans organizing pneumonia should
be carefully evaluated for the presence of chronic
GVHDmanifestation in other organs. Successful lung
transplantation has been performed in a small number
of patients with end-stage pulmonary chronic GVHD
[84]. Outside of HCT, an underlying autoimmune
process is implicated by the association of BO with
lung transplantation, collagen-vascular diseases, and
viral infections [85,86].
Even without BO, pulmonary sicca and bronchi-
ectasis lead to frequent infections and bacterial colo-
nization, often with Pseudomonas species. Patients with
chronic GVHD are also at risk for chronic sinopul-
monary disease, which may be relatively asymptomatic
given the extent of involvement. The sinuses should
be considered as a potential fever source in any patient
with chronic GVHD.
Musculoskeletal System
Muscle cramps are a common symptom, although
the pathophysiology is not understood. Myositis, with
tender muscles and increased muscle enzymes, may
start as a proximal myopathy, but is rare and does not
explain the frequent occurrence of severe cramps. Fas-
cial involvement in sclerodermatous GVHD is usually
associated with skin changes, but may develop with
normal, but ﬁxed overlying skin [87]. Fasciitis often
affects forearms and legs causing signiﬁcant limita-
tions in range of motion and joint contractures. Pa-
tients with restricted range of motion beneﬁt from a
regular program of physical therapy and deep muscle
fascial massage. Serial assessments of joints should
document range of motion.
Hematopoietic System
Cytopenias are common in patients with chronic
GVHD. They may be a result of stromal damage or
caused by autoimmune processes. Thrombocytopenia
S. J. Lee et al.
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at the time of chronic GVHD diagnosis has been
associated with a poor prognosis [66,88,89]. Eosino-
philia may be seen and may be an indicator of chronic
GVHD activity.
Other Organ Systems
Pericardial and pleural effusions can cause com-
pressive loss of function and may require drainage and
sclerosis. Peripheral edema may be severe. Myasthenia
gravis and peripheral neuropathy also have been at-
tributed to chronic GVHD. Women may develop
vaginal or vulvar lichenoid changes, ulcers, web for-
mation, and strictures, and should have a biopsy to
conﬁrm the diagnosis if no other organs are involved.
Topical corticosteroids can be effective treatment for
vaginal chronic GVHD, and mechanical or surgical
dilation may be necessary for relief of symptoms.
In pediatrics, chronic GVHD or its treatment can
inhibit growth, although most children do catch up
once chronic GVHD is controlled and immunosup-
pression is tapered. Chronic GVHD involvement of
heart, kidney, and central nervous system is question-
able despite occasional rare reports.
Immunodeficiency
Chronic GVHD causes profound immune dys-
function [90-93], and most chronic GVHD deaths are
attributable to infection. Defects in mucosal integrity,
immunosuppressive medications, and reduced number
and function of mature T and B cells contribute to the
high fatality rate from bacterial, fungal, and viral
pathogens [90-93]. Functional asplenia with an in-
creased susceptibility to encapsulated bacteria, partic-
ularly pneumococcus, is common, and circulating
Howell-Jolly bodies may be seen on peripheral blood
smear. Patients are also at high risk for invasive fungal
infections and Pneumocystis carinii pneumonia [94].
EVALUATION OF SUSPECTED CHRONIC GVHD
Many patients will have returned to the care of
their primary hematologist-oncologist when chronic
GVHD develops. Although not every rash or GI
symptom represents GVHD, the accurate and timely
diagnosis of chronic GVHD is an important ﬁrst step
in its successful treatment. Because therapy for
chronic GVHD is highly immunosuppressive and
must be continued for a prolonged time, it is impor-
tant to conﬁrm the diagnosis before initiating therapy.
Conversely, subtle manifestations of chronic GVHD
may go undiagnosed for months, and this delay may
make successful treatment and rehabilitation difﬁcult.
For example, the diagnosis of fasciitis without skin
changes may be difﬁcult to recognize, but systematic
assessment of range of motion of wrists and ankles
may detect early signs before permanent disability. In
addition, pulmonary function testing at 3 months and
at 1 year after transplantation may detect early signs of
BO before symptoms become apparent.
Once chronic GVHD is diagnosed, intermittent
evaluation at an experienced center can help guide
management. In a series of 123 patients referred to
Johns Hopkins for the management of refractory
chronic GVHD, 9 patients were judged to never have
had chronic GVHD and 26 patients had inactive dis-
ease [95]. Restaging with the use of the Schirmer’s
test, pulmonary function tests, gynecological evalua-
tion, liver function, complete blood cell counts, and
medical photographs if skin involvement is present is
helpful to assess the extent of the disease. A morbidity
scale can be used to record the severity of manifesta-
tion of the chronic GVHD at the time of diagnosis,
whenever therapy is changed, and at yearly intervals if
treatment continues or if manifestations of chronic
GVHD persist.
PREVENTION
Although acute GVHD is a predictor for develop-
ment of chronic GVHD, successful efforts to decrease
acute GVHD have not resulted in decreased rates of
chronic GVHD. The two notable exceptions are T-
cell depletion and use of umbilical cord blood as a
stem cell source because lower rates of both acute and
chronic GVHD are observed with these approaches
[96,97]. Speciﬁc attempts to decrease chronic GVHD
rates through prolongation of CSA administration,
addition of Ig or thalidomide, and preemptive treat-
ment on the basis of subclinical chronic GVHD found
in skin and lip biopsy specimens [52,98,99] have
proven unsuccessful (Table 5).
TREATMENT OF CHRONIC GVHD
Because the main manifestation of this disease is
immunodeﬁciency, patient education and infection
prophylaxis are very important components of chronic
GVHD management. Infection is the leading cause of
death in patients with chronic GVHD. Prophylaxis
against P carinii should be administered to all patients
undergoing treatment of chronic GVHD for 6
months after discontinuation of immunosuppressive
medications. Lifelong splenic dysfunction occurs with
chronic GVHD, and prophylaxis against encapsulated
bacteria is recommended. The guidelines published by
the American Heart Association for endocarditis pro-
phylaxis should be followed when patients are under-
going dental or other invasive procedures. Patients
treated with topical steroids for oral GVHD should be
treated with clotrimazole troches or nystatin swishes
to prevent oral candidiasis. Patients at risk for late
CMV disease (receiving systemic corticosteroids)
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should have CMV activity monitored closely and
treatment initiated or reactivated. Patients should re-
ceive prophylatic acyclovir for prevention of varicella
zoster virus reactivation during the ﬁrst year after the
transplantation and later if systemic immunosuppres-
sion is still needed to control chronic GVHD. Some
centers administer intravenous IgG to patients with
hypogammaglobulinemia if levels are400 mg/dL) to
maintain serum IgG levels 500 mg/dL. Posttrans-
plantation vaccination guidelines are available on the
Centers for Disease Control and Prevention web site
(www. cdc.gov/mmwr/mmwr_rr.html) [100]. Patients
Table 5. Prevention Trials (All Patients Received Bone Marrow)
Intervention Population Comment
Chronic GVHD
Conclusions Reference
Randomized trials of acute
GVHD prophylaxis
Cyclosporine/steroids vs.
cyclosporine alone
HLA-matched sibling
recipients at high risk of
relapse
posttransplantation,
N  60
Decreased incidence of acute
GVHD with combination
prophylaxis but similar
survival
Higher incidence of
chronic GVHD (44% vs.
21%, P  .02) with
combination prophylaxis
125
Cyclosporine/methotrexate
vs. methotrexate alone
HLA-matched sibling
recipients with aplastic
anemia, N  46
Decreased incidence of acute
GVHD with combination
prophylaxis and better
survival
Trend toward higher
chronic GVHD in
combination prophylaxis
(58% vs. 36%, P  .18)
126
CSA/methotrexate vs.
CSA alone
HLA-matched sibling
recipients with AML in
CR1 or CML, N  93
Decreased incidence of acute
GVHD with combination
prophylaxis and improved
survival
No difference 127
CSA/methotrexate /
steroids
HLA-matched (N  122)
or 1 antigen mismatched
(N  25) recipients,
heterogeneous diseases
Higher incidence of
chronic GVHD (62% vs.
40%, P  .01) in group
receiving steroids
independent of acute
GVHD
128
CSA/steroids /
methotrexate
HLA-matched sibling
recipients with acute
leukemia in CR1 or
CML, N  149
No difference 129
Randomized trials aimed
directly at chronic
GVHD prevention
Dose of CSA (high vs. low
dose)
HLA-matched sibling
recipients with acute
leukemia, N  81
Low-dose CSA associated with
lower relapse rate
No difference 130
Duration of CSA
administration (24 mo
vs. 6 mo)
Prior acute GVHD or skin
biopsy positive for
subclinical chronic
GVHD, N  162
Incidence of chronic GVHD in
6-mo CSA arm lower than
historical controls
No difference 124
Duration of CSA
administration (6 mo vs.
60 d)
No active acute GVHD,
N  103
Onset of chronic GVHD more
rapid in short CSA arm,
higher treatment-related
mortality in short CSA arm
if prior acute GVHD
No difference in incidence 131
CSA/methotrexate /
thalidomide
90% matched sibling
recipients, N  54
Double-blinded, study closed
early due to lower survival
and more chronic GVHD in
the group receiving
thalidomide
Thalidomide associated
with more chronic
GVHD and worse
survival
123
Ig vs. no Ig Heterogeneous population,
N  250
Ig arm had more total
infections in year 2 than
control patients
No difference 83
Different doses of Ig Heterogeneous population,
N  627
Double-blinded, 3 dose levels of
IgG, similar rates of infection
and interstitial pneumonitis
No difference 132
AML indicates acute myelogenous leukemia; CR1, ﬁrst complete remission; CML, chronic myelogenous leukemia.
Reprinted with permission from Lee et al. Chronic graft-versus-host disease. In: Atkinson et al. Clinical Bone Marrow and Blood Stem Cell
Transplantation. 3rd ed. Cambridge, UK: Cambridge University Press [in press].
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with chronic GVHD should not receive live virus
vaccinations such as measles, mumps, and rubella.
The most widely used ﬁrst-line therapy for treat-
ment of chronic GVHD is CSA and prednisone, ad-
ministered on alternating days. Sullivan et al reported
that prednisone alone is superior to prednisone plus
azathioprine for primary treatment of patients with
standard-risk extensive chronic GVHD [98]. How-
ever, in patients classiﬁed as high risk on the basis of
platelet counts  100  109/L, treatment with pred-
nisone alone resulted in only a 26% 5-year survival
rate. When a similar group of patients was treated
with alternating day CSA and prednisone, the 5-year
survival rate exceeded 50% [88]. After this encourag-
ing report, most centers adopted this regimen for
initial treatment of all patients, not just those deemed
at high risk. Patients start treatment with daily pred-
nisone at 1 mg/kg/d and daily CSA at 10 mg/kg/d
divided twice a day. If chronic GVHD is stable or
improving after 2 weeks, prednisone is tapered by
25% per week to a target dosage of 1 mg/kg every
other day. After successful completion of this steroid
taper, CSA is reduced by 25% per week to alternate-
day dosing of 10 mg/kg/d divided twice a day, every
other day. If the disease has completely resolved, pa-
tients are slowly weaned from both medications after
9 months, with dose reductions approximately every 2
weeks. Patients with incomplete responses are kept on
therapy for 3 more months and then re-evaluated. If
patients fail to respond by 3 months or show progres-
sive disease, salvage regimens are warranted [101].
Until recently, there was no data on the effective-
ness of this regimen in standard-risk patients. Flowers
recently reviewed the success of initial combination
therapy for patients treated in the 1980s. She reported
a nonrelapse mortality rate of 21% in standard-risk
patients (N  126) and 39% in high-risk patients
(N  111), deﬁned by progressive onset or thrombo-
cytopenia. Successful discontinuation of all immuno-
suppressive medications eventually occurred for 60%
of standard-risk patients and 40% of high-risk patients
[102]. Koc et al recently reported the long-awaited
results of a study comparing prednisone alone to pred-
nisone plus CSA in patients with extensive chronic
Table 6. Primary Therapy for Chronic GVHD
Treatment N Comments Conclusions
Group I: untreated, group II:
corticosteroids and/or anti-
thymocyte globulin, group III:
corticosteroids and
cyclophosphamide,
procarbazine, or azathioprine
52 Sequential study, alive and free of
disability: untreated 15%,
corticosteroids and/or anti-thymocyte
globulin 23%, combination therapy 71%
Most effective regimen was
corticosteroids and azathioprine [133]
Corticosteroids / azathioprine 179 Standard-risk patients were randomized,
high-risk patients given single-agent
prednisone, 40% of patients in each
group had subclinical disease only
Higher mortality from infection if
azathioprine part of initial treatment
regimen. In high-risk patients (platelets
< 100000), prednisone alone resulted in
26% survival [98]
Alternating-day corticosteroids
and CSA
61 Phase 2 design, high-risk extensive chronic
GVHD, 40 given primary therapy, 21
given salvage, long-term survival >50%
compared with historical control of 26%
Alternating-day, combination therapy
better [88]
Cyclosporine, steroids /
thalidomide
54 Randomized, unblinded trial, patients with
extensive chronic GVHD.
Closed early (target enrollment N  134)
after interim analysis showed slow
accrual and higher response rates in
both arms than projected [134]
Steroids, CSA or tacrolimus, /
thalidomide
51 Randomized, placebo-controlled trial of
thalidomide added to standard upfront
therapy in higher-risk patients with
thrombocytopenia or progressive
presentation.
Closed early (target enrollment N  132)
after interim analysis showed slow
accrual and only 42% probability of
reaching statistical significance by
enrolling remainder of patients [135]
Steroids / CSA 287 Randomized, unblinded trial, enrolled
1985-1992
Disease-free survival was lower in the
combination arm (hazard ratio 1.51;
95% CI, 1.03-2.21; P  .03) in
multivariate analysis. Transplant-
related mortality, relapse, secondary
chronic GVHD therapy, rates and
discontinuation of all
immunosuppressive therapy were not
different [103]
Reprinted with permission from Lee et al. Chronic graft-versus-host disease. In: Atkinson et al. Clinical Bone Marrow and Blood Stem Cell
Transplantation. 3rd ed. Cambridge, UK: Cambridge University Press [in press].
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Table 7. Secondary Therapy for Chronic GVHD
Agent
Published Success
Rate
Hypothesized Mechanism of
Action Side Effects Reference
High-dose
corticosteroids
48% major
response rate
(N  56)
Lympholytic at these doses Infection, glucose intolerance,
osteoporosis, avascular
necrosis, cataracts,
psychological effects including
psychosis, insomnia
136
Tacrolimus 35% response rate
(N  39)
Binds to FKBP-12 (FK binding
protein) and inhibits T-
lymphocyte activation,
concentrates in liver
Renal dysfunction, neurotoxicity,
hypertension
137, 138
Mycophenolate mofetil 46% objective
response
(N  26)
Prodrug of mycophenolic acid that
is a noncompetitive reversible
inhibitor of inosine
monophosphate dehydrogenase.
Cytostatic for T and B
lymphocytes because they lack
salvage pathways
Nausea, vomiting, diarrhea,
neutropenia
139, 140
Rapamycin Not available Binds to FKBP-12 and mammalian
target of rapamycin to inhibit
cytokine-driven T-cell
proliferation
Hyperlipidemia, hypertension,
rash
Extracorporeal
photopheresis
33%-80%
N  (11-18)
Induces apoptosis in alloreactive T
cells, normalization of CD4/CD8
ratios by decreasing CD8 cells,
increases natural killer cells,
decreases dendritic cells
GI upset, potential need for
central IV access
141-144
Psoralen and UVA 40% CR, 38% PR
(N  11-40)
Interferes with antigen
presentation and inflammatory
cytokine production by
Langerhan’s cells, increases IL-
10 production by keratinocytes
Increase in skin cancer,
phototoxicity, nausea,
hepatoxicity
145-149
UV-B radiation Case series Treats epidermis only, induces IL-
10 in human epidermal cells
Increase in skin cancer,
phototoxicity
150
Thalidomide 9%-42% CR rate
(N  14-80)
Anti-inflammatory and
immunosuppressive properties
Neuropathy, somnolence,
constipation, neutropenia
104-106, 151
Etretinate (no longer
available), acitretin
74% improvement
(N  27)
Synthetic vitamin A derivative,
may affect production of
cytokines
Skin scaling, breakdown, nail
cracking, xerosis, cheilitis,
pruritis, rare pseudotumor
cerebri
152
Azathioprine Not available Cleaved to mercaptopurine GI symptoms, neutropenia,
thrombocytopenia
Hydroxychloroquine 9% CR and 44%
PR (N  40)
Interferes with antigen processing
and presentation, proliferation,
TNF production, and
cytotoxicity, synergistic with
CSA and tacrolimus in vitro
GI symptoms, rare retinal
toxicity
153
Ursodeoxycholic acid 33% decreased in
bilirubin levels,
but not
sustained off
therapy
(N  12)
Replaces native human bile acids,
reduces class I HLA expression
on hepatocytes
Diarrhea, abdominal pain,
headache
154
Clofazimine 55% PR
(N  22)
Atypical immunomodulatory
effects
Abdominal cramping,
hyperpigmentation
155
Anti-thymocyte
globulin
Not available In vivo T-cell depletion Anaphylaxis, serum sickness
Daclizumab Not available Humanized anti–IL-2 receptor
antibody
None
Infliximab Reported in
abstracts
Chimeric IgG monoclonal
antibody, binds to TNF and
prevents binding with receptors
Hypersensitivity reactions,
infections
2-deoxycoformycin Reported in
abstracts
Inhibits adenosine deaminase Nausea, vomiting,
myelosuppression, rash,
headache
S. J. Lee et al.
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GVHD without thrombocytopenia [103]. In this trial
(N  287 evaluable patients), the cumulative inci-
dence of transplant-related mortality, survival, relapse,
need for secondary chronic GVHD therapy, and dis-
continuation of immunosuppressive medications were
not signiﬁcantly different between the 2 arms. Intrigu-
ingly, survival without recurrent malignancy was bet-
ter in the prednisone-only arm (P  .03) although the
incidence of avascular necrosis was also higher. Thus,
there is no evidence that initial combination therapy
improved control of chronic GVHD in patients with
platelet counts  100  109/L. The uncertainty re-
garding the choice of frontline therapy emphasizes the
importance of enrolling patients on clinical trials so
that fundamental questions about the pathogenesis
and treatment of chronic GVHD may be answered.
Currently 2 large randomized trials are planned or
underway for frontline therapy. One trial through the
Children’s Oncology Group is looking at the addition
of hydroxycholoroquine to CSA plus prednisone. The
other multi-centered trial organized by the Fred
Hutchinson Cancer Research Center is examining the
addition of mycophenolate mofetil to prednisone plus
calcineurin inhibitor in patients with extensive chronic
GVHD or high-risk features. Table 6 reviews pub-
lished trials of initial treatment for chronic GVHD.
SECONDARY THERAPIES
If patients fail to respond or progress through
steroid-based therapy then secondary therapy is indi-
cated. Steroid-refractory chronic GVHD is formally
deﬁned as either failure to improve after at least 2
months, or progression after 1 month of standard
immunosuppressive therapy, including corticosteroids
and CSA [104,105]. A number of phase 2 trials of
secondary or salvage regimens have been published,
and most report a success rate of 25% to 50%. How-
ever, most trials contain 40 or fewer patients. Re-
ported response rates are usually based on 4 catego-
ries: complete (resolution of all chronic GVHD
manifestations), partial (50% but less than complete
organ responses), no response (50% response), and
progression (worsening while on therapy) [104,106].
Table 7 provides information about salvage therapies
in chronic GVHD. A multicenter, randomized trial
with extracorporeal photopheresis is currently being
conducted in the United States and Europe for pa-
tients with corticosteroid-dependent or refractory
chronic GVHD with skin involvement.
IMPACT OF CHRONIC GVHD ON MAJOR
TRANSPLANTATION OUTCOMES
Nonrelapse Mortality
Chronic GVHD is the major cause of nonrelapse
mortality in patients surviving more than 2 years after
allogeneic transplantation, and increasing severity of
chronic GVHD is associated with higher nonrelapse
mortality rates [4,82] (Figure 2). Infection from a
broad array of pathogens is the major cause of death,
followed by progressive organ failure from chronic
GVHD involvement. De novo chronic GVHD occurs
later than the other forms of chronic GVHD and does
not seem to adversely affect survival [107]. In aplastic
anemia and refractory anemias where the risk of re-
lapse and death from the primary disease is low,
chronic GVHD has a substantial adverse impact on
survival that has not improved signiﬁcantly during the
past 30 years [2,108].
Table 7. (Continued)
Agent
Published Success
Rate
Hypothesized Mechanism of
Action Side Effects References
Rituximab Case report Chimeric anti-CD20 monoclonal
antibody
Allergic reactions 156
Total lymphoid
radiation
Case series Leukopenia 157, 158
Topical azathioprine Case report Purine analog metabolized to 6
mercaptopurine
Rash, fever, pancreatitis,
arthralgias, malaise, nausea,
diarrhea, pancytopenia,
hepatitis, infections,
malignancy
159
Topical tacrolimus Case series 0.1% ointment Localized skin burning, pruritis,
irritation
160
Opthalmic cyclosporine Case series 1% solution None 161
IV lidocaine Case report Vascular and anti-inflammatory
properties
Seizures, drowsiness, tremors,
hypotension
162
IV indicates intravenous; CR, complete response; PR, partial response.
Reprinted with permission from Lee et al. Chronic graft-versus-host disease. In: Atkinson et al. Clinical Bone Marrow and Blood Stem Cell
Transplantation. 3rd ed. Cambridge, UK: Cambridge University Press [in press].
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Graft-versus-Malignancy Effect
Chronic GVHD is associated with lower relapse
rates in both early- and advanced-stage leukemia
[3,107,109-113]. However, the nature of this graft-
versus-malignancy effect is poorly understood, and it
is not known whether the protective effect relies on
development of overt chronic GVHD or is durable
once chronic GVHD resolves [110]. Recent observa-
tional data suggest that increased severity of chronic
GVHD is not associated with a decreased relapse risk
(Figure 2). Nevertheless, studies examining preventive
and treatment strategies should carefully follow up
relapse rates, especially in situations where disease is
advanced or cure is thought to be heavily reliant on an
intact graft-versus-malignancy effect. For example,
eradication of Philadelphia chromosome– positive
cells in patients with chronic myeloid leukemia was
correlated with development of chronic GVHD in
one study [114].
Impact on Functional Status and Quality of Life
Chronic GVHD is associated with substantial
quality of life deﬁcits, particularly in the areas of
physical and functional status [5,115-117]. In addition,
patients with chronic GVHD report more speciﬁc
symptoms, such as rashes, mouth sores, and frequent
infections than unaffected individuals [7,118]. Social
and emotional functioning and satisfaction with trans-
plantation are relatively preserved, although chronic
GVHD is associated with decreased general health
status, sexual inactivity, and loss of employment in
long-term survivors [69,117,119-122]. In addition,
long-term treatment with corticosteroids for chronic
GVHD may result in compromised quality of life due
to the signiﬁcant morbidity associated with this treat-
ment. A 30-item survey allowing patient self-report of
chronic GVHD symptoms has been validated [113].
FUTURE DIRECTIONS
Efforts to prevent the development of chronic
GVHD, including the use of Ig and thalidomide, have
been unsuccessful [83,123]. Likewise, trials of pro-
longed administration of CSA found no difference in
chronic GVHD or mortality when CSA was given for
24 months rather then 6 months [124]. Current trans-
plantation practices, including the use of DLIs and
PBSCs, older patient age, and increasing use of unre-
lated and mismatched stem cell donors make it likely
that chronic GVHD is going to be a progressively
more common problem. Ongoing research to further
characterize the pathogenesis of this disease is crucial
to the development of new therapeutic approaches,
whereas well-organized, multicenter trials are needed
to test clinical questions.
ACKNOWLEDGMENTS
Supported in part by National Institutes of Health
grant no. CA75267-05 and the Amy Strelzer-Manas-
evit Scholars Program. Supported by grants HL36444,
CA18221, and CA18029 from the National Institutes of
Health, Department of Health and Human Services.
The authors wish to thank Paul Martin for helpful com-
ments.
REFERENCES
1. Gilman AL, Schultz KR. Treatment of chronic GVHD. Bone
Marrow Transplant. 2000;26:460-462.
2. Goerner M, Gooley T, Flowers ME, et al. Morbidity and
mortality of chronic GVHD after hematopoietic stem cell
transplantation from HLA-identical siblings for patients with
aplastic or refractory anemias. Biol Blood Marrow Transplant.
2002;8:47-56.
3. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-
versus-host disease: association with treatment-related mortal-
ity and relapse. Blood. 2002;100:406-414.
4. Socie G, Stone JV, Wingard JR, et al. Long-term survival and
late deaths after allogeneic bone marrow transplantation. Late
Effects Working Committee of the International Bone Mar-
row Transplant Registry. N Engl J Med. 1999;341:14-21.
5. Syrjala KL, Chapko MK, Vitaliano PP, et al. Recovery after
allogeneic marrow transplantation: prospective study of pre-
dictors of long-term physical and psychosocial functioning.
Bone Marrow Transplant. 1993;11:319-327.
6. Duell T, van Lint MT, Ljungman P, et al. Health and func-
tional status of long-term survivors of bone marrow transplan-
tation. EBMT Working Party on Late Effects and EULEP
Study Group on Late Effects. European Group for Blood and
Marrow Transplantation. Ann Intern Med. 1997;126:184-192.
7. Sutherland HJ, Fyles GM, Adams G, et al. Quality of life
following bone marrow transplantation: a comparison of pa-
tient reports with population norms. Bone Marrow Transplant.
1997;19:1129-1136.
8. Beschorner WE, Tutschka PJ, Santos GW. Chronic graft-
versus-host disease in the rat radiation chimera. I. Clinical
features, hematology, histology, and immunopathology in
long- term chimeras. Transplantation. 1982;33:393-399.
9. Tutschka PJ, Teasdall R, Beschorner WE, et al. Chronic
graft-versus-host disease in the rat radiation chimera. II. Im-
munological evaluation in long-term chimeras. Transplanta-
tion. 1982;34:289-294.
10. Atkinson K, Shulman HM, Deeg HJ, et al. Acute and chronic
graft-versus-host disease in dogs given hemopoietic grafts
from DLA-nonidentical littermates. Two distinct syndromes.
Am J Pathol. 1982;108:196-205.
11. DeClerck Y, Draper V, Parkman R. Clonal analysis of murine
graft-vs-host disease. II. Leukokines that stimulate ﬁbroblast
proliferation and collagen synthesis in graft-vs. host disease.
J Immunol. 1986;136:3549-3552.
12. Hamilton BL, Parkman R. Acute and chronic graft-versus-
host disease induced by minor histocompatibility antigens in
mice. Transplantation 1983;36:150-5.
13. Nonomura A, Kono N, Minato H, et al. Diffuse biliary tract
involvement mimicking primary sclerosing cholangitis in an
experimental model of chronic graft-versus-host disease in
mice. Pathol Int. 1998;48:421-427.
S. J. Lee et al.
228
14. Slayback DL, Dobkins JA, Harper JM, et al. Genetic factors
inﬂuencing the development of chronic graft-versus-host dis-
ease in a murine model. Bone Marrow Transplant. 2000;26:931-
938.
15. Zhang Y, McCormick LL, Desai SR, et al. Murine scleroder-
matous graft-versus-host disease, a model for human sclero-
derma: cutaneous cytokines, chemokines, and immune cell
activation. J Immunol. 2002;168:3088-3098.
16. Okamoto I, Kohno K, Tanimoto T, et al. IL-18 prevents the
development of chronic graft-versus-host disease in mice.
J Immunol. 2000;164:6067-6074.
17. Reinherz EL, Parkman R, Rappeport J, et al. Aberrations of
suppressor T cells in human graft-versus-host disease. N Engl
J Med. 1979;300:1061-1068.
18. Lichtman AH, Krenger W, Ferrara JL. Cytokine networks.
In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host
Disease. Second Edition. New York: Marcel Dekker, Inc.; 1997:
179-218.
19. Aractingi S, Chosidow O. Cutaneous graft-versus-host dis-
ease. Arch Dermatol. 1998;134:602-612.
20. Ratanatharathorn V, Ayash L, Lazarus HM, et al. Chronic
graft-versus-host disease: clinical manifestation and therapy.
Bone Marrow Transplant. 2001;28:121-129.
21. Ochs LA, Miller WJ, Filipovich AH, et al. Predictive factors
for chronic graft-versus-host disease after histocompatible sib-
ling donor bone marrow transplantation. Bone Marrow Trans-
plant. 1994;13:455-460.
22. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral
blood stem cell transplantation may be associated with a high
risk of chronic graft-versus-host disease. Blood. 1997;90:4705-
4709.
23. Solano C, Martinez C, Brunet S, et al. Chronic graft-versus-
host disease after allogeneic peripheral blood progenitor cell
or bone marrow transplantation from matched related donors.
A case-control study. Spanish Group of Allo-PBT. Bone Mar-
row Transplant. 1998;22:1129-1135.
24. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised,
prospective comparison of allogeneic bone marrow and pe-
ripheral blood progenitor cell transplantation in the treatment
of haematological malignancies. Bone Marrow Transplant.
1998;22:1145-1151.
25. Scott MA, Gandhi MK, Jestice HK, et al. A trend towards an
increased incidence of chronic graft-versus-host disease fol-
lowing allogeneic peripheral blood progenitor cell transplan-
tation: a case controlled study. Bone Marrow Transplant. 1998;
22:273-276.
26. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem
cells compared with bone marrow as a source of hematopoietic
cells for allogeneic transplantation. IBMTR Histocompatibil-
ity and Stem Cell Sources Working Committee and the Eu-
ropean Group for Blood and Marrow Transplantation
(EBMT). Blood. 2000;95:3702-3709.
27. Snowden JA, Nivison-Smith I, Atkinson K, et al. Allogeneic
PBPC transplantation: an effect on incidence and distribution
of chronic graft-versus-host disease without long-term sur-
vival beneﬁt? Bone Marrow Transplant. 2000;25:119-120.
28. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-
versus-host disease after allogeneic peripheral- blood stem-
cell and bone marrow transplantation: a meta-analysis. J Clin
Oncol. 2001;19:3685-3691.
29. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stim-
ulating factor (G-CSF)-primed allogeneic bone marrow: sig-
niﬁcantly less graft-versus-host disease and comparable en-
graftment to G-CSF-mobilized peripheral blood stem cells.
Blood. 2001;98:3186-3191.
30. Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor
leukocyte infusions in 140 patients with relapsed malignancy
after allogeneic bone marrow transplantation. J Clin Oncol.
1997;15:433-444.
31. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-
dose and escalating-dose regimens of donor lymphocyte infu-
sion for relapse after allografting for chronic myeloid leuke-
mia. Blood. 2000;95:67-71.
32. Hess A, Thoburn C, Chen W, et al. Autoreactive T-Cell
subsets in acute and chronic syngeneic graft-versus- host dis-
ease. Transplant Proc. 2001;33:1754-1756.
33. Sullivan KM, Parkman R. The pathophysiology and treatment
of graft-versus-host disease. Clin Haematol. 1983;12:775-789.
34. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting
thymic function after allogeneic hematopoietic stem cell trans-
plantation. Blood. 2001;97:1458-1466.
35. Parkman R. Chronic graft-versus-host disease. Curr Opin He-
matol. 1998;5:22-25.
36. Rouquette-Gally AM, Boyeldieu D, Prost AC, et al. Autoim-
munity after allogeneic bone marrow transplantation. A study
of 53 long-term-surviving patients. Transplantation. 1988;46:
238-240.
37. Aractingi S, de The H, Gluckman E, et al. PML is expressed
in chronic graft-versus-host disease lesions. Bone Marrow
Transplant. 1997;19:1125-1128.
38. Soderberg C, Sumitran-Karuppan S, Ljungman P, et al.
CD13-speciﬁc autoimmunity in cytomegalovirus-infected
immunocompromised patients. Transplantation. 1996;61:594-
600.
39. Soderberg C, Larsson S, Rozell BL, et al. Cytomegalovirus-
induced CD13-speciﬁc autoimmunity—a possible cause of
chronic graft-vs-host disease. Transplantation. 1996;61:600-
609.
40. Barak V, Levi-Schaffer F, Nisman B, et al. Cytokine dysregu-
lation in chronic graft versus host disease. Leuk Lymphoma.
1995;17:169-173.
41. Liem LM, Fibbe WE, van Houwelingen HC, et al. Serum
transforming growth factor-beta1 levels in bone marrow
transplant recipients correlate with blood cell counts and
chronic graft-versus- host disease. Transplantation. 1999;67:
59-65.
42. Korholz D, Kunst D, Hempel L, et al. Decreased interleukin
10 and increased interferon-gamma production in patients
with chronic graft-versus-host disease after allogeneic bone
marrow transplantation. Bone Marrow Transplant. 1997;19:
691-695.
43. Nelson JL, Furst DE, Maloney S, et al. Microchimerism and
HLA-compatible relationships of pregnancy in scleroderma.
Lancet. 1998;351:559-562.
44. Evans PC, Lambert N, Maloney S, et al. Long-term fetal
microchimerism in peripheral blood mononuclear cell subsets
in healthy women and women with scleroderma. Blood. 1999;
93:2033-2037.
45. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in
chronic graft-versus-host disease in patients with aplastic ane-
mia treated by marrow transplantation from HLA- identical
siblings. Ann Intern Med. 1983;98:461-466.
46. Bostrom L, Ringden O, Jacobsen N, et al. A European mul-
ticenter study of chronic graft-versus-host disease. The role of
Chronic GVHD Review
229BB&MT
cytomegalovirus serology in recipients and donors—acute
graft- versus-host disease, and splenectomy. Transplantation.
1990;49:1100-1105.
47. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for
chronic graft-versus-host disease after HLA-identical sibling
bone marrow transplantation. Blood. 1990;75:2459-2464.
48. Ringden O, Paulin T, Lonnqvist B, et al. An analysis of factors
predisposing to chronic graft-versus-host disease. Exp Hema-
tol. 1985;13:1062-1067.
49. Carlens S, Ringden O, Remberger M, et al. Risk factors for
chronic graft-versus-host disease after bone marrow trans-
plantation: a retrospective single centre analysis. Bone Marrow
Transplant. 1998;22:755-761.
50. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-
versus-host disease after allogeneic blood stem cell transplan-
tation. Blood. 2001;98:1695-1700.
51. Wagner JL, Seidel K, Boeckh M, et al. De novo chronic
graft-versus-host disease in marrow graft recipients given
methotrexate and cyclosporine: risk factors and survival. Biol
Blood Marrow Transplant. 2000;6:633-639.
52. Wagner JL, Flowers ME, Longton G, et al. The development
of chronic graft-versus-host disease: an analysis of screening
studies and the impact of corticosteroid use at 100 days after
transplantation. Bone Marrow Transplant. 1998;22:139-146.
53. Remberger M, Aschan J, Lonnqvist B, et al. An ethnic role for
chronic, but not acute, graft-versus-host disease after HLA-
identical sibling stem cell transplantation. Transplant Proc.
2001;33:1769-1770.
54. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in
granulocyte colony-stimulating factor-mobilized peripheral
blood mononuclear cell grafts affects engraftment kinetics and
development of extensive chronic graft-versus-host disease
after human leukocyte antigen-identical sibling transplanta-
tion. Blood. 2001;98:3221-3227.
55. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of
unrelated donor umbilical cord blood in 102 patients with
malignant and nonmalignant diseases: inﬂuence of CD34 cell
dose and HLA disparity on treatment-related mortality and
survival. Blood. 2002;100:1611-1618.
56. Korbling M, Anderlini P. Peripheral blood stem cell versus
bone marrow allotransplantation: does the source of hemato-
poietic stem cells matter? Blood. 2001;98:2900-2908.
57. Remberger M, Ringden O, Blau IW, et al. No difference in
graft-versus-host disease, relapse, and survival comparing pe-
ripheral stem cells to bone marrow using unrelated donors.
Blood. 2001;98:1739-1745.
58. Elmaagacli AH, Basoglu S, Peceny R, et al. Improved disease-
free-survival after transplantation of peripheral blood stem
cells as compared with bone marrow from HLA-identical
unrelated donors in patients with ﬁrst chronic phase chronic
myeloid leukemia. Blood. 2002;99:1130-1135.
59. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosph-
amide compared with total-body irradiation plus cyclophos-
phamide before marrow transplantation for myeloid leukemia:
long-term follow-up of 4 randomized studies. Blood. 2001;98:
3569-3574.
60. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III
study comparing methotrexate and tacrolimus (prograf,
FK506) with methotrexate and cyclosporine for graft-versus-
host disease prophylaxis after HLA-identical sibling bone
marrow transplantation. Blood. 1998;92:2303-2314.
61. Atkinson K, Downs K. Omission of day 11 methotrexate does
not appear to inﬂuence the incidence of moderate to severe
acute graft-versus-host disease, chronic graft-versus-host dis-
ease, relapse rate or survival after HLA- identical sibling bone
marrow transplantation. Bone Marrow Transplant. 1995;16:
755-758.
62. Sullivan KM. Graft-versus-host disease. In: Thomas ED,
Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation.
Malden, MA: Blackwell Science, Inc.; 1999:515-536.
63. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man. A long-term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.
64. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of
death from chronic graft-versus-host disease after bone mar-
row transplantation. Blood. 1989;74:1428-1435.
65. Morton A, Anasetti C, Gooley T, et al. Chronic graft-versus-
host disease (GVHD) following unrelated donor transplanta-
tion. Blood. 1997;90:590a.
66. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a
prognostic model for grading chronic graft-versus-host dis-
ease. Blood. 2001;97:1219-1226.
67. Arora M, Burns LJ, Davies SM, et al. Chronic graft versus host
disease: a prospective cohort study. Biol Blood Marrow Trans-
plant. 2003;9:38-45.
68. Gaziev D, Lucarelli G, Polchi P, et al. A three or more drug
combination as effective therapy for moderate or severe
chronic graft-versus-host disease. Bone Marrow Transplant.
2001;27:45-51.
69. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-
host disease and other late complications of bone marrow
transplantation. Semin Hematol. 1991;28:250-259.
70. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of
chronic graft-versus-host disease after transplantation of pe-
ripheral blood stem cells versus bone marrow in allogeneic
recipients: long-term follow-up of a randomized trial. Blood.
2002;100:415-419.
71. Graze PR, Gale RP. Chronic graft versus host disease: a
syndrome of disordered immunity. Am J Med. 1979;66:611-
620.
72. Knobler HY, Sagher U, Peled IJ, et al. Tolerance to donor-
type skin in the recipient of a bone marrow allograft. Treat-
ment of skin ulcers in chronic graft-versus-host disease with
skin grafts from the bone marrow donor. Transplantation.
1985;40:223-225.
73. Hart DE, Simko M, Harris E. How to produce moisture
chamber eyeglasses for the dry eye patient. J Am Optom Assoc.
1994;65:517-522.
74. Schubert MM, Sullivan KM, Morton TH, et al. Oral mani-
festations of chronic graft-v-host disease. Arch Intern Med.
1984;144:1591-1595.
75. Nagler R, Marmary Y, Krausz Y, et al. Major salivary gland
dysfunction in human acute and chronic graft- versus-host
disease (GVHD). Bone Marrow Transplant. 1996;17:219-224.
76. Akpek G, Valladares JL, Lee L, et al. Pancreatic insufﬁciency
in patients with chronic graft-versus-host disease. Bone Mar-
row Transplant. 2001;27:163-166.
77. Zauner C, Rabitsch W, Schneeweiss B, et al. Energy and
substrate metabolism in patients with chronic extensive graft-
versus-host disease. Transplantation. 2001;71:524-528.
78. Jacobsohn DA, Margolis J, Doherty J, et al. Weight loss and
malnutrition in patients with chronic graft-versus-host dis-
ease. Bone Marrow Transplant. 2002;29:231-236.
79. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-
S. J. Lee et al.
230
versus-host disease of the liver: presentation as an acute hep-
atitis. Hepatology. 2000;32:1265-1271.
80. Arai S, Lee LA, Vogelsang GB. A systematic approach to
hepatic complications in hematopoietic stem cell transplanta-
tion. J Hematother Stem Cell Res. 2002;11:215-229.
81. Rhodes DF, Lee WM, Wingard JR, et al. Orthotopic liver
transplantation for graft-versus-host disease following bone
marrow transplantation. Gastroenterology. 1990;99:536-538.
82. Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung
disease after allogeneic marrow transplantation. Clinical pre-
sentation and course. Ann Intern Med. 1989;111:368-376.
83. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of
long-term administration of intravenous immunoglobulin to
prevent late infection and chronic graft-vs.-host disease after
marrow transplantation: clinical outcome and effect on subse-
quent immune recovery. Biol Blood Marrow Transplant. 1996;
2:44-53.
84. Boas SR, Noyes BE, Kurland G, et al. Pediatric lung trans-
plantation for graft-versus-host disease following bone mar-
row transplantation. Chest. 1994;105:1584-1586.
85. Holland HK, Wingard JR, Beschorner WE, et al. Bronchioli-
tis obliterans in bone marrow transplantation and its relation-
ship to chronic graft-v-host disease and low serum IgG. Blood.
1988;72:621-627.
86. Philit F, Wiesendanger T, Archimbaud E, et al. Post-trans-
plant obstructive lung disease (“bronchiolitis obliterans”): a
clinical comparative study of bone marrow and lung transplant
patients. Eur Respir J. 1995;8:551-558.
87. Janin A, Socie G, Devergie A, et al. Fasciitis in chronic graft-
versus-host disease. A clinicopathologic study of 14 cases. Ann
Intern Med. 1994;120:993-998.
88. Sullivan KM,Witherspoon RP, Storb R, et al. Alternating-day
cyclosporine and prednisone for treatment of high-risk
chronic graft-v-host disease. Blood. 1988;72:555-561.
89. Anasetti C, Rybka W, Sullivan KM, et al. Graft-v-host disease
is associated with autoimmune-like thrombocytopenia. Blood.
1989;73:1054-1058.
90. Siadak M, Sullivan KM. The management of chronic graft-
versus-host disease. Blood Rev. 1994;8:154-160.
91. Storek J, Witherspoon RP, Webb D, et al. Lack of B cells
precursors in marrow transplant recipients with chronic graft-
versus-host disease. Am J Hematol. 1996;52:82-89.
92. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmu-
nity post-bone marrow transplantation. Bone Marrow Trans-
plant. 1998;22:873-881.
93. Maury S, Mary JY, Rabian C, et al. Prolonged immune deﬁ-
ciency following allogeneic stem cell transplantation: risk fac-
tors and complications in adult patients. Br J Haematol. 2001;
115:630-641.
94. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus
host disease is associated with long-term risk for pneumococ-
cal infections in recipients of bone marrow transplants. Blood.
2000;95:3683-3686.
95. Jacobsohn DA, Montross S, Anders V, et al. Clinical impor-
tance of conﬁrming or excluding the diagnosis of chronic
graft-versus-host disease. Bone Marrow Transplant. 2001;28:
1047-1051.
96. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood
as a source of hematopoietic stem cells for transplantation into
unrelated recipients. N Engl J Med. 1996;335:157-166.
97. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome
of cord-blood transplantation from related and unrelated do-
nors. Eurocord Transplant Group and the European Blood
and Marrow Transplantation Group. N Engl J Med. 1997;337:
373-381.
98. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and
azathioprine compared with prednisone and placebo for treat-
ment of chronic graft-v-host disease: prognostic inﬂuence of
prolonged thrombocytopenia after allogeneic marrow trans-
plantation. Blood. 1988;72:546-554.
99. Loughran TP, Jr., Sullivan K, Morton T, et al. Value of day
100 screening studies for predicting the development of
chronic graft-versus-host disease after allogeneic bone marrow
transplantation. Blood. 1990;76:228-234.
100. Centers for Disease Control, Infectious Disease Society of
America, American Society for Blood and Marrow Transplan-
tation. Guidelines for preventing opportunistic infections
among hematopoietic stem cell transplant recipients. Biol Blood
Marrow Transplant. 2000;6:659-727.
101. Vogelsang GB. How I treat chronic graft-versus-host disease.
Blood. 2001;97:1196-1201.
102. Flowers MED. Traditional treatment of chronic graft-versus-
host disease. Blood Marrow Transplant Rev 2002;12:5-8.
103. Koc S, Leisenring W, Flowers MED, et al. Therapy for
chronic graft-versus-host disease: a randomized trial compar-
ing cyclosporine plus prednisone versus prednisone alone.
Blood. 2002;100:48-51.
104. Parker PM, Chao N, Nademanee A, et al. Thalidomide as
salvage therapy for chronic graft-versus-host disease. Blood.
1995;86:3604-3609.
105. Browne PV, Weisdorf DJ, DeFor T, et al. Response to tha-
lidomide therapy in refractory chronic graft-versus-host dis-
ease. Bone Marrow Transplant. 2000;26:865-869.
106. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for
the treatment of chronic graft-versus-host disease. N Engl
J Med. 1992;326:1055-1058.
107. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic
effect of chronic graft-versus-host disease: contribution to
improved survival after allogeneic marrow transplantation.
N Engl J Med. 1981;304:1529-1533.
108. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome
after marrow transplantation for severe aplastic anemia. Blood.
1998;91:3637-3645.
109. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic
effect of graft-versus-host disease in human recipients of allo-
geneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
110. Sullivan KM, Weiden PL, Storb R, et al. Inﬂuence of acute
and chronic graft-versus-host disease on relapse and survival
after bone marrow transplantation from HLA-identical sib-
lings as treatment of acute and chronic leukemia [published
erratum appears in Blood 1989;74:1180]. Blood. 1989;73:1720-
1728.
111. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-
leukemia reactions after bone marrow transplantation. Blood.
1990;75:555-562.
112. Ringden O, Labopin M, Gluckman E, et al. Strong antileu-
kemic effect of chronic graft-versus-host disease in allogeneic
marrow transplant recipients having acute leukemia treated
with methotrexate and cyclosporine. The Acute Leukemia
Working Party of the European Group for Blood and Marrow
Transplantation (EBMT). Transplant Proc. 1997;29:733-734.
113. Brunet S, Urbano-Ispizua A, Ojeda E, et al. Favourable effect
of the combination of acute and chronic graft-versus- host
disease on the outcome of allogeneic peripheral blood stem
Chronic GVHD Review
231BB&MT
cell transplantation for advanced haematological malignancies.
Br J Haematol. 2001;114:544-550.
114. Pichert G, Roy DC, Gonin R, et al. Distinct patterns of
minimal residual disease associated with graft- versus-host
disease after allogeneic bone marrow transplantation for
chronic myelogenous leukemia. J Clin Oncol. 1995;13:1704-
1713.
115. Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244
recipients of allogeneic bone marrow transplantation. Br J
Haematol. 2000;110:614-619.
116. Heinonen H, Volin L, Uutela A, et al. Quality of life and
factors related to perceived satisfaction with quality of life
after allogeneic bone marrow transplantation. Ann Hematol.
2001;80:137-143.
117. Lee S, Cook EF, Soiffer R, et al. Development and validation
of a scale to measure symptoms of chronic graft-versus-host
disease. Biol Blood Marrow Transplant. 2002;8:444-452.
118. Schmidt GM, Niland JC, Forman SJ, et al. Extended fol-
low-up in 212 long-term allogeneic bone marrow transplant
survivors. Issues of quality of life. Transplantation. 1993;55:
551-557.
119. Wingard JR, Curbow B, Baker F, et al. Health, functional
status, and employment of adult survivors of bone marrow
transplantation. Ann Intern Med. 1991;114:113-118.
120. Andrykowski MA, Greiner CB, Altmaier EM, et al. Quality of
life following bone marrow transplantation: ﬁndings from a
multicentre study. Br J Cancer. 1995;71:1322-1329.
121. Marks DI, Gale DJ, Vedhara K, et al. A quality of life study in
20 adult long-term survivors of unrelated donor bone marrow
transplantation. Bone Marrow Transplant. 1999;24:191-195.
122. Socie G, Mary JY, Esperou H, et al. Health and functional
status of adult recipients 1 year after allogeneic haematopoi-
etic stem cell transplantation. Br J Haematol. 2001;113:194-
201.
123. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of
thalidomide prophylaxis on chronic graft-vs.-host disease. Biol
Blood Marrow Transplant. 1996;2:86-92.
124. Kansu E, Gooley T, Flowers ME, et al. Administration of
cyclosporine for 24 months compared with 6 months for
prevention of chronic graft-versus-host disease: a prospective
randomized clinical trial. Blood. 2001;98:3868-3870.
125. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclo-
sporine plus methylprednisolone for prophylaxis of graft-ver-
sus-host disease: a prospective, randomized trial. Blood. 1997;
89:3880-3887.
126. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease
prevention by methotrexate combined with cyclosporin com-
pared to methotrexate alone in patients given marrow grafts
for severe aplastic anaemia: long-term follow-up of a con-
trolled trial [see comments]. Br J Haematol. 1989;72:567-572.
127. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclo-
sporine versus cyclosporine alone for prophylaxis of graft-
versus-host disease in patients given HLA-identical marrow
grafts for leukemia: long-term follow-up of a controlled trial.
Blood. 1989;73:1729-1734.
128. Storb R, Pepe M, Anasetti C, et al. What role for prednisone
in prevention of acute graft-versus-host disease in patients
undergoing marrow transplants? Blood. 1990;76:1037-1045.
129. Ross M, Schmidt GM, Niland JC, et al. Cyclosporine, meth-
otrexate, and prednisone compared with cyclosporine and
prednisone for prevention of acute graft-vs.-host disease: ef-
fect on chronic graft-vs.-host disease and long-term survival.
Biol Blood Marrow Transplant. 1999;5:285-291.
130. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk
of leukemia relapse with high-dose cyclosporine A after allo-
geneic marrow transplantation for acute leukemia. Blood. 1991;
77:1423-1428.
131. Storb R, Leisenring W, Anasetti C, et al. Methotrexate and
cyclosporine for graft-vs.-host disease prevention: what length
of therapy with cyclosporine? Biol Blood Marrow Transplant.
1997;3:194-201.
132. Winston DJ, Antin JH, Wolff SN, et al. A multicenter, ran-
domized, double-blind comparison of different doses of intra-
venous immunoglobulin for prevention of graft-versus-host
disease and infection after allogeneic bone marrow transplan-
tation. Bone Marrow Transplant. 2001;28:187-196.
133. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-
versus-host disease in 52 patients: adverse natural course and
successful treatment with combination immunosuppression.
Blood. 1981;57:267-276.
134. Arora M, Wagner JE, Davies SM, et al. Randomized clinical
trial of thalidomide, cyclosporine, and prednisone versus cy-
closporine and prednisone as initial therapy for chronic graft-
versus-host disease. Biol Blood Marrow Transplant. 2001;7:265-
273.
135. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for
treatment of patients with chronic graft-versus-host disease.
Blood. 2000;96:3995-3996.
136. Akpek G, Lee SM, Anders V, et al. A high-dose pulse steroid
regimen for controlling active chronic graft-versus-host dis-
ease. Biol Blood Marrow Transplant. 2001;7:495-502.
137. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK 506 rescue in
chronic graft-versus-host-disease after bone marrow trans-
plantation. Transplant Proc. 1991;23:3225-3227.
138. Carnevale-Schianca F, Martin P, Sullivan K, et al. Changing
from cyclosporine to tacrolimus as salvage therapy for chronic
graft-versus-host disease. Biol Blood Marrow Transplant. 2000;
6:613-620.
139. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil
for the treatment of acute and chronic GVHD in bone mar-
row transplant patients. Bone Marrow Transplant. 1998;22:61-
65.
140. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for
refractory chronic graft-versus-host disease with mycopheno-
late mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:
517-520.
141. Dall’Amico R, Rossetti F, Zulian F, et al. Photopheresis in
paediatric patients with drug-resistant chronic graft- versus-
host disease. Br J Haematol. 1997;97:848-854.
142. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use
of extracorporeal photochemotherapy in the treatment of se-
vere acute and chronic graft-versus-host disease. Blood. 1998;
92:3098-3104.
143. Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal pho-
topheresis (ECP) in the treatment of chronic graft- versus-
host disease (GVHD). Bone Marrow Transplant. 1999;23:881-
887.
144. Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory
effects of extracorporeal photochemotherapy in patients with
extensive chronic graft-versus-host disease. Blood. 2001;98:
1622-1625.
145. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsora-
S. J. Lee et al.
232
len and ultraviolet A therapy for cutaneous manifestations of
graft-versus-host disease. Transplantation. 1990;50:807-811.
146. Jampel RM, Farmer ER, Vogelsang GB, et al. PUVA therapy
for chronic cutaneous graft-vs-host disease. Arch Dermatol.
1991;127:1673-1678.
147. Kapoor N, Pelligrini AE, Copelan EA, et al. Psoralen plus
ultraviolet A (PUVA) in the treatment of chronic graft versus
host disease: preliminary experience in standard treatment
resistant patients. Semin Hematol. 1992;29:108-112.
148. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of
chronic graft-versus-host disease with ultraviolet irradiation
and psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061-
1067.
149. Redding SW, Callander NS, Haveman CW, et al. Treatment
of oral chronic graft-versus-host disease with PUVA therapy:
case report and literature review. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 1998;86:183-187.
150. Enk CD, Elad S, Vexler A, et al. Chronic graft-versus-host
disease treated with UVB phototherapy. Bone Marrow Trans-
plant. 1998;22:1179-1183.
151. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in
the treatment of refractory chronic graft- versus-host disease
following bone marrow transplantation in children. Bone Mar-
row Transplant. 1998;21:577-581.
152. Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate
therapy for refractory sclerodermatous chronic graft-versus-
host disease. Blood. 1999;93:66-70.
153. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine
for the treatment of chronic graft-versus-host disease. Biol
Blood Marrow Transplant. 2000;6:327-334.
154. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic
acid treatment of refractory chronic graft-versus-host disease
of the liver. Ann Intern Med. 1992;116:624-629.
155. Lee SJ, Wegner SA, McGarigle CJ, et al. Treatment of
chronic graft-versus-host disease with clofazimine. Blood.
1997;89:2298-2302.
156. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20
chimeric monoclonal antibody treatment of refractory im-
mune- mediated thrombocytopenia in a patient with chronic
graft-versus-host disease. Ann Intern Med. 2000;133:275-279.
157. Socie G, Devergie A, Cosset JM, et al. Low-dose (one gray)
total-lymphoid irradiation for extensive, drug- resistant
chronic graft-versus-host disease. Transplantation. 1990;49:
657-658.
158. Bullorsky EO, Shanley CM, Stemmelin GR, et al. Total lym-
phoid irradiation for treatment of drug resistant chronic
GVHD. Bone Marrow Transplant. 1993;11:75-76.
159. Epstein JB, Nantel S, Sheoltch SM. Topical azathioprine in
the combined treatment of chronic oral graft-versus-host dis-
ease. Bone Marrow Transplant. 2000;25:683-687.
160. Aoyama H, Tabata N, Tanaka M, et al. Successful treatment
of resistant facial lesions of atopic dermatitis with 0.1% FK506
ointment. Br J Dermatol. 1995;133:494-496.
161. Kiang E, Tesavibul N, Yee R, et al. The use of topical
cyclosporin A in ocular graft-versus-host-disease. Bone Mar-
row Transplant. 1998;22:147-151.
162. Voltarelli JC, Ahmed H, Paton EJ, et al. Beneﬁcial effect of
intravenous lidocaine in cutaneous chronic graft-versus-host
disease secondary to donor lymphocyte infusion. Bone Marrow
Transplant. 2001;28:97-99.
Chronic GVHD Review
233BB&MT
